BioTuesdays

Author - Stephen Kilmer

Acasti Pharma

Mackie puts Acasti Pharma under review; removes PT

Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...

Xenon Pharma

WB starts Xenon Pharma at OP; estimated fair value $27

William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...

X4 Pharma

HCW starts X4 Pharma at buy; PT $22

H.C. Wainwright launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $22 price target. The stock closed at $10.39 on Jan. 6. The company’s lead product candidate, mavorixafor, is a potential...

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

Ocugen

HCW starts Ocugen at buy; PT $1.25

H.C. Wainwright launched coverage of Ocugen (NASDAQ:OCGN) with a “buy” rating and price target of $1.25. The stock closed at 36 cents on Dec. 19. Ocugen is developing therapies for rare and underserved eye diseases and...

Season’s Greetings (and JPM 2020)

Wow, what an interesting year 2019 has turned out to be!On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and...

mesoblast

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

Diffusion Pharma

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

Subscribe

Sign up to our weekly BioTuesdays newsletter.